RESPA 787 (Respa-PE 600 mg / 18 mg)
Pill imprint RESPA 787 has been identified as Respa-PE 600 mg / 18 mg.
Guaifenesin/phenylephrine is used in the treatment of sinus symptoms; cough and nasal congestion and belongs to the drug class upper respiratory combinations. Risk cannot be ruled out during pregnancy. Guaifenesin/phenylephrine 600 mg / 18 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- RESPA 787
- Strength:
- 600 mg / 18 mg
- Color:
- White
- Shape:
- Elliptical / Oval
- Availability:
- Rx and/or OTC
- Drug Class:
- Upper respiratory combinations
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Respa Pharmaceuticals
- National Drug Code (NDC):
- 60575-0787
More about guaifenesin/phenylephrine
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- En Español
- 9 Reviews – Add your own review/rating
- Drug class: upper respiratory combinations
Consumer resources
- Guaifenesin/phenylephrine
- Guaifenesin/phenylephrine controlled-release tablets
- Guaifenesin/phenylephrine liquid
- Guaifenesin/phenylephrine suspension
- Guaifenesin/phenylephrine sustained-release capsules
- More... (2)
Other brands: Entex LA, Deconex IR, Deconex, Rescon-GG, More... (21)
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
